Institutional Investors Are Dumping Oncomed Pharmaceuticals Inc (NASDAQ:OMED)

Sentiment for Oncomed Pharmaceuticals Inc (NASDAQ:OMED)

Oncomed Pharmaceuticals Inc (NASDAQ:OMED) institutional sentiment decreased to 0.52 in Q4 2018. Its down -0.61, from 1.13 in 2018Q3. The ratio has worsened, as 13 institutional investors started new or increased equity positions, while 25 decreased and sold holdings in Oncomed Pharmaceuticals Inc. The institutional investors in our partner’s database now hold: 16.90 million shares, down from 17.31 million shares in 2018Q3. Also, the number of institutional investors holding Oncomed Pharmaceuticals Inc in their top 10 equity positions was flat from 0 to 0 for the same number . Sold All: 13 Reduced: 12 Increased: 7 New Position: 6.

OncoMed Pharmaceuticals, Inc. discovers and develops cancer stem cell and immuno-oncology therapeutics. The company has market cap of $34.43 million. The companyÂ’s product candidates and preclinical programs include demcizumab (anti-DLL4, OMP-21M18), a humanized monoclonal antibody, in Phase II trial for pancreatic cancer, a randomized Phase II trial in non-small cell lung cancer, and a Phase Ib trial for solid tumor; tarextumab (anti-Notch2/3, OMP-59R5) that targets the Notch2 and Notch3 receptors, which is in Phase II clinical trial for small cell lung cancer; vantictumab (anti-Fzd, OMP-18R5) in two Phase Ib clinical trials for breast and pancreatic cancer; ipafricept (Fzd8-Fc, OMP-54F28), a fusion protein based on Frizzled8 receptor, which is in two Phase Ib clinical trials for ovarian and pancreatic cancer; and navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets DLL4 and vascular endothelial growth factor, which is in Phase Ia single-agent clinical trial for solid tumors, and two Phase Ib clinical trial for ovarian and metastatic colorectal cancer. It currently has negative earnings. It is also developing anti-RSPO3 (OMP-131R10), a monoclonal antibody, in Phase Ia/b clinical trial for solid tumor and metastatic colorectal cancer; brontictuzumab (anti-Notch1, OMP-52M51) targeting the Notch1 receptor, in Phase Ib clinical trial for colorectal cancer; anti-tigit (OMP-313M32), a T-cell immunoglobulin and ITIM domain protein, in Phase I clinical trial for tumor; and GITRL-Fc trimer (OMP-336B11), a preclinical product candidate targeting glucocorticoid-induced tumor necrosis factor receptor and its ligand.

It closed at $0.89 lastly. It is down 66.23% since May 8, 2018 and is downtrending. It has underperformed by 70.60% the S&P500.

Harbourvest Partners Llc holds 0.67% of its portfolio in OncoMed Pharmaceuticals, Inc. for 1.90 million shares. Bvf Inc Il owns 4.04 million shares or 0.39% of their US portfolio. Moreover, Birchview Capital Lp has 0.12% invested in the company for 172,557 shares. The New York-based Perceptive Advisors Llc has invested 0.05% in the stock. Cannell Peter B & Co Inc, a New York-based fund reported 303,071 shares.

More notable recent OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) news were published by: Seekingalpha.com which released: “Bristol-Myers’ Collaboration Deal: Accelerating Potential Creation Value For Compugen Ltd. – Seeking Alpha” on November 27, 2018, also Globenewswire.com with their article: “OncoMed to Present at Two Upcoming Investor Conferences in September – GlobeNewswire” published on August 29, 2018, Nasdaq.com published: “3 Cheap Biotech Stocks The Big Boys Are Buying – Nasdaq” on May 12, 2017. More interesting news about OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) were released by: Seekingalpha.com and their article: “Buy Shares Of This Overlooked Biotech With Catalysts – Seeking Alpha” published on September 27, 2016 as well as Globenewswire.com‘s news article titled: “OncoMed’s Phase 2 Trial of Tarextumab in Small Cell Lung Cancer Does Not Meet Endpoints – GlobeNewswire” with publication date: April 17, 2017.

OncoMed Pharmaceuticals, Inc. (NASDAQ:OMED) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.